Fecal Microbiota Transplantation for Clostridioides difficile Infection in Immunocompromised Pediatric Patients

Author:

Conover Katie R.1,Absah Imad2,Ballal Sonia3,Brumbaugh David4,Cho Stanley5,Cardenas Maria C.2,Knackstedt Elizabeth Doby6,Goyal Alka7,Jensen M. Kyle8,Kaplan Jess L.9,Kellermayer Richard6,Kociolek Larry K.10,Michail Sonia11,Oliva-Hemker Maria12,Reed Anna W.12,Weatherly Madison3,Kahn Stacy A.3,Nicholson Maribeth R.13

Affiliation:

1. Department of General Pediatrics, Vanderbilt University Medical Center, Nashville, TN

2. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mayo Clinic Children’s Center, Rochester, MN

3. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Boston Children’s Hospital, Boston, MA

4. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children’s Hospital Colorado, Aurora, CO

5. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Texas Children’s Hospital, Houston, TX

6. Division of Pediatric Infectious Disease, University of Utah, Primary Children’s Hospital, Salt Lake City, UT

7. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Lucile Packard Children’s Hospital, Palo Alto, CA

8. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Utah, Primary Children’s Hospital, Salt Lake City, UT

9. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Mass General Hospital for Children, Boston, MA

10. Division of Pediatric Infectious Diseases, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

11. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Children’s Hospital Los Angeles, Los Angeles, CA

12. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Johns Hopkins Children’s Center, Baltimore, MD

13. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Monroe Carell Jr. Children’s Hospital, Nashville, TN.

Abstract

Objectives: We sought to evaluate the safety and effectiveness of fecal microbiota transplantation (FMT) for recurrent Clostridioides difficile infection (CDI) in pediatric immunocompromised (IC) patients. Methods: This is a multicenter retrospective cohort study of pediatric participants who underwent FMT between March 2013 and April 2020 with 12-week follow-up. Pediatric patients were included if they met the definition of IC and were treated with FMT for an indication of recurrent CDI. We excluded patients over 18 years of age, those with incomplete records, insufficient follow-up, or not meeting study definition of IC. We also excluded those treated for Clostridioides difficile recurrence without meeting the study definition and those with inflammatory bowel disease without another immunocompromising condition. Results: Of 59 pediatric patients identified at 9 centers, there were 42 who met inclusion and no exclusion criteria. Included patients had a median age of 6.7 years. Etiology of IC included: solid organ transplantation (18, 43%), malignancy (12, 28%), primary immunodeficiency (10, 24%), or other chronic conditions (2, 5%). Success rate was 79% after first FMT and 86% after 1 or more FMT. There were no statistically significant differences in patient characteristics or procedural components when patients with a failed FMT were compared to those with a successful FMT. There were 15 total serious adverse events (SAEs) in 13 out of 42 (31%) patients that occurred during the follow-up period; 4 (9.5%) of which were likely treatment-related. There were no deaths or infections with multidrug resistant organisms during follow-up and all patients with a SAE fully recovered. Conclusions: The success rate of FMT for recurrent CDI in this pediatric IC cohort is high and mirrors data for IC adults and immunocompetent children. FMT-related SAEs do occur (9.5%) and highlight the need for careful consideration of risk and benefit.

Publisher

Wiley

Subject

Gastroenterology,Pediatrics, Perinatology and Child Health

Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3